Cyhoeddiad
2024
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia (10.1038/s41375-024-02405-5)
2023
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186(16), pp. 3333-3349., article number: E27. (10.1016/j.cell.2023.06.020)
2020
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
2016
- Zabkiewicz, J. et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7(13), pp. 16650-16662. (10.18632/oncotarget.7692)
2015
- Lazenby, M., Hills, R., Burnett, A. K. and Zabkiewicz, J. 2015. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39(6), pp. 617-624. (10.1016/j.leukres.2015.03.016)
2014
- Zabkiewicz, J., Pearn, L., Hills, R., Morgan, R. G., Tonks, A., Burnett, A. K. and Darley, R. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)
2013
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
2011
- Collins, A. M., Zabkiewicz, J., Ghiggi, C., Hauser, J. C., Burnett, A. K. and Mann, S. 2011. Tris(8-hydroxyquinolinato)gallium(III)-loaded copolymer micelles as cytotoxic nanoconstructs for cosolvent-free organometallic drug delivery. Small 7(12), pp. 1635-1640. (10.1002/smll.201100405)
2010
- Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, R. G., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
2009
- Shorning, B. et al. 2009. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS ONE 4(1), article number: e4264. (10.1371/journal.pone.0004264)
2005
- Zabkiewicz, J. 2005. In vivo modelling of tumour suppressor gene function. PhD Thesis, Cardiff University.
2004
- Zabkiewicz, J. and Clarke, A. R. 2004. DNA damage-induced apoptosis: insights from the mouse. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1705(1), pp. 17-25. (10.1016/j.bbcan.2004.09.002)
2003
- Sansom, O. J., Zabkiewicz, J., Bishop, S. M., Guy, J., Bird, A. and Clarke, A. R. 2003. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22(46), pp. 7130-7136. (10.1038/sj.onc.1206850)
Articles
- Halilovic, M. et al. 2024. Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins.. Leukemia (10.1038/s41375-024-02405-5)
- Dolton, G. et al. 2023. Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy. Cell 186(16), pp. 3333-3349., article number: E27. (10.1016/j.cell.2023.06.020)
- Zabkiewicz, J. et al. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191(2), pp. 231-242. (10.1111/bjh.16665)
- Zabkiewicz, J. et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7(13), pp. 16650-16662. (10.18632/oncotarget.7692)
- Lazenby, M., Hills, R., Burnett, A. K. and Zabkiewicz, J. 2015. The HSP90 inhibitor ganetespib: a potential effective agent for Acute Myeloid Leukemia in combination with cytarabine. Leukemia Research 39(6), pp. 617-624. (10.1016/j.leukres.2015.03.016)
- Zabkiewicz, J., Pearn, L., Hills, R., Morgan, R. G., Tonks, A., Burnett, A. K. and Darley, R. 2014. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica 99(5), pp. 858-864. (10.3324/haematol.2013.096487)
- Hole, P. S. et al. 2013. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood 122(19), pp. 3322-3330. (10.1182/blood-2013-04-491944)
- Collins, A. M., Zabkiewicz, J., Ghiggi, C., Hauser, J. C., Burnett, A. K. and Mann, S. 2011. Tris(8-hydroxyquinolinato)gallium(III)-loaded copolymer micelles as cytotoxic nanoconstructs for cosolvent-free organometallic drug delivery. Small 7(12), pp. 1635-1640. (10.1002/smll.201100405)
- Zabkiewicz, J., Pearn, L., Hills, R. K., Morgan, R. G., Burnett, A. K., Tonks, A. and Darley, R. L. 2010. PDK1 overexpression in acute myeloid leukemia; Clinical significance and potential as a therapeutic target [Abstract]. Blood 116(21), pp. 892-893.
- Shorning, B. et al. 2009. Lkb1 deficiency alters goblet and paneth cell differentiation in the small intestine. PLoS ONE 4(1), article number: e4264. (10.1371/journal.pone.0004264)
- Zabkiewicz, J. and Clarke, A. R. 2004. DNA damage-induced apoptosis: insights from the mouse. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1705(1), pp. 17-25. (10.1016/j.bbcan.2004.09.002)
- Sansom, O. J., Zabkiewicz, J., Bishop, S. M., Guy, J., Bird, A. and Clarke, A. R. 2003. MBD4 deficiency reduces the apoptotic response to DNA-damaging agents in the murine small intestine. Oncogene 22(46), pp. 7130-7136. (10.1038/sj.onc.1206850)
Thesis
- Zabkiewicz, J. 2005. In vivo modelling of tumour suppressor gene function. PhD Thesis, Cardiff University.
Contact Details
ZabkiewiczJ1@caerdydd.ac.uk
+44 29207 42499
Prif Adeilad yr Ysbyty, Ystafell Ystafell 80G, 4ydd llawr B-C Coridor Cyswllt, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
+44 29207 42499
Prif Adeilad yr Ysbyty, Ystafell Ystafell 80G, 4ydd llawr B-C Coridor Cyswllt, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN